H ypertensive nephropathy is a major cause of end-stage kidney disease. It has been estimated that 51% to 63% of patients with chronic kidney disease are hypertensive, and the renin-angiotensin system is central to the pathogenesis of hypertensive nephropathy with progressive renal fibrosis and inflammation. 1, 2 Angiotensin II is the main effector of reninangiotensin system and directly contributes to the progression of chronic kidney disease via hemodynamic and nonhemodynamic functions. 3, 4 Increasing evidence suggests that the angiotensin-converting enzyme-2 (ACE2)-angiotensin (1-7)-Mas axis functions as a counterbalance against ACE-angiotensin II-AT1 (type 1 angiotensin II) receptor axis. In the normal kidney, ACE2 mRNA and protein levels are high, whereas ACE expression levels are moderate. [5] [6] [7] However, in patients or animals with hypertensive and diabetic kidney diseases, expression of ACE2 is largely reduced and associated with a marked increase in expression of ACE and AT1, [5] [6] [7] suggesting an ACE:ACE2 imbalance underlying the pathogenesis of hypertensive nephropathy.
The protective role of ACE2 in chronic kidney disease has been demonstrated in several animal models including angiotensin II-induced hypertensive heart disease and diabetes mellitus, 8, 9 ischemia and reperfusion kidney injury, 10 unilateral ureteral obstruction, 11 and 5/6 nephrectomized kidney disease. 12 Moreover, genetic deletion of ACE2 or pharmacological inhibition of ACE2 with a specific inhibitor (MLN-4760) induces renal oxidative stress and promotes diabetic renal injury. 13, 14 In contrast, overexpression of ACE2 or treatment with recombinant ACE2 attenuates angiotensin II-triggered oxidative stress, renal inflammation, and fibrosis. 15, 16 It is now clear that angiotensin II signals through the AT1-ERK (extracellular signal-regulated)/p38 MAP (mitogen-activated protein) kinases, TGF-β (transforming growth factor β)/Smad2/3, and NF-κB (nuclear factor κ-light-chain-enhancer of activated B cells) pathways to Abstract-Angiotensin-converting enzyme-2 (ACE2) is downregulated in hypertensive nephropathy. The present study investigated the mechanisms whereby loss of ACE2 promoted angiotensin II-induced hypertensive nephropathy in ACE2 gene knockout mice. We found that compared with wild-type animals, mice lacking ACE2 developed much more severe hypertensive nephropathy in response to chronic angiotensin II infusion, including higher levels of blood pressure, urinary protein excretion, serum creatinine, and progressive renal fibrosis and inflammation. Mechanistic studies revealed that worsening kidney injury in ACE2 knockout mice was associated with an increase in Smurf2 (Smad-specific E3 ubiquitin protein ligase 2), a decrease in renal Smad7, and marked activation of TGF-β (transforming growth factor β)/Smad3 and NF-κB (nuclear factor κ-light-chain-enhancer of activated B cells) signaling, suggesting that Smurf2-dependent Smad7 ubiquitin degradation may be a key mechanism whereby loss of ACE2 promotes angiotensin II-induced TGF-β/ Smad3 and NF-κB-mediated hypertensive nephropathy. This was validated by restoring Smad7 locally in the kidneys of ACE2 knockout mice to block angiotensin II-induced TGF-β/Smad3-mediated renal fibrosis and NF-κB-driven renal inflammation. Moreover, we found that angiotensin II could induce microRNA-21 in the mouse kidney and in cultured mesangial cells via a Smad3-dependent mechanism, which was enhanced by deleting ACE2 but inhibited by overexpressing renal Smad7. promote renal oxidative stress and fibrosis. 3, 7, 14, 17 However, signaling mechanisms whereby ACE2 protects against angiotensin II-induced TGF-β/Smad and NF-κB-dependent renal fibrosis and inflammation remain largely unclear. In this study, we aimed to define the protective mechanisms of ACE2 in hypertensive nephropathy in ACE2 gene knockout mice induced by chronic subcutaneous angiotensin II infusion.
Methods
Angiotensin II-Induced Hypertensive Model in ACE2 Knockout Mice ACE2 knockout mice in C57BL/6 background and wild-type (WT) littermates (male mice aged 8-10 weeks, n=8-10 per group) were kindly provided by Professor Josef M. Penninger (Institute of Molecular Biotechnology of the Austrian Academy of Sciences, Vienna, Austria) and were generated as previously described. 15 To confirm the protective role of ACE2 in a moderate-to-severe hypertensive nephropathy induced by chronic subcutaneous angiotensin II infusion, we performed a dose-dependent titration study and found that angiotensin II at a dose of 1.46 mg/kg per day was optimal to induce moderate hypertensive nephropathy without detectable stress, as reported previously. 17 An osmotic minipump (Model 2004; ALZA Corp, Palo Alto, CA) containing the designated dose of angiotensin II or normal saline control was subcutaneously implanted at the dorsum of the neck to induce hypertension for 28 days. Renal cortical tissues were collected by carefully removing the renal pelvis and medullary tissues for Western blot analysis and real-time polymerase chain reaction (PCR). Blood pressure was measured using the tail-cuff method in conscious mice according to the manufacturer's instruction (CODA noninvasive blood pressure system; Kent Scientific, Torrington, CT). 17 Albuminuria was detected by competitive ELISA according to the manufacturer's protocol (Exocell, Philadelphia, PA). Twenty-four-hour urine samples were used for microalbuminuria assay analyzed in the Bio-Tek uQuant spectrophotometer (Bio-Tek Instruments, Inc, Ontario, Canada). Creatinine was examined using an enzymatic kit provided by Stanbio Laboratories (Stanbio Laboratories, Boerne, TX) following the manufacturer's protocol. The experimental procedures were approved by the Animal Experimental Committee at The Chinese University of Hong Kong.
Smad7 Gene Therapy
To confirm the protective mechanism and therapeutic role of Smad7 in angiotensin II-induced hypertensive nephropathy in ACE2 knockout mice, pTRE-Flag-M2-Smad7 and Tet-on plasmids (4 μg/g body weight, respectively) were prepared in 200 μL normal saline and mixed with microbubbles (Sonovue Bracco Imaging B.V., Plan-LesQuates Geneve, Switzerland) gently in 1:1 volume ratio. pTRE empty vector (Clontech, Palo Alto, CA) and Tet-on plasmids (Clontech) were used as the negative control. The mixed plasmids/microbubbles were then delivered via the tail vein into ACE2 knockout mice, followed by placement of the ultrasound transducer (Therasonic 450; ElectroMedical Supplies (Greenham) Ltd, Wantage, Oxfordshire, England) on the mouse back skin against kidneys to deliver ultrasound pulse frequency of 1 MHz at 2 W/cm 2 , as previously described. 18, 19 A total of 5 minutes of ultrasound treatment to each kidney was applied, and immediately after ultrasound treatment, doxycycline at a dose of 200 μg/mL was intraperitoneally injected into both Smad7-treated or untreated mice, followed by additional maintenance doxycycline (200 μg/mL) in the daily drinking water over the entire treatment period to induce stable expression of Smad7. According to previous studies, 18, 19 pTRE-Flag-M2-Smad7 or pTRE empty vectors were delivered into the kidney every 2 weeks to maintain normal levels of Smad7 during the 4-week period.
Immunohistochemistry
Immunohistochemistry was performed on paraffin sections using a microwave-based antigen retrieval technique. 20 Antibodies used in this study are as follows: MCP-1 (monocyte chemoattractant protein-1), tumor necrosis factor α, IL-1β (interleukin-1β), and TGF-β1 (Santa Cruz Biotechnology, Santa Cruz, CA), collagen I (Southern Tech, Birmingham, AL), α-SMA (α-smooth muscle actin; Sigma, St Louis, MO), and rat antimouse monoclonal antibody to macrophages (F4/80; Serotec, Oxford, United Kingdom), rabbit polyclonal antibodies to CD3 + T cells (Abcam, Cambridge, United Kingdom), and phospho-NF-κB/p65 (ser276). All tissue sections (except those for α-SMA) were counterstained with hematoxylin. Quantification of immunostaining was performed in coded slides.
20,21

Real-Time PCR
Renal cortex was frozen at −80°C for gene expression analysis by quantitative real-time PCR. 21 The PCR primers for detecting mouse mRNA expression targeted IL-1β, tumor necrosis factor α, MCP-1, collagen I, α-SMA, TGF-β1, Smad7, Smurf2 (Smad-specific E3 ubiquitin protein ligase 2), GAPDH, and microRNA-21 (miR-21; Table  S1 in the online-only Data Supplement). 11, [21] [22] [23] For miR-21 expression, renal RNA was isolated using TRIzol. 22 The housekeeping genes, GAPDH or U6, were used as internal controls where indicated.
Western Blot Analysis
Renal cortical tissue samples were lysed using radioimmunoprecipitation assay buffer for Western blot analysis. 19, 21 After protein was transferred onto a nitrocellulose membrane, the membrane was incubated overnight with primary antibodies against phospho-NF-κB/p65 (ser276); phospho-Smad3 (Cell Signaling Technology, MA); Smad2/3, Smad7, Smurf2, and NF-κB/p65 (Santa Cruz Biotechnology); p-IκBα (phosphonated inhibitor of nuclear factor κB) and IκBα (Cell Signaling Technology); α-SMA (Sigma); collagen I (Southern Tech); and GAPDH (Chemicon, Temecula, CA) followed by the LI-COR IRDye 800-labeled secondary antibodies (Rockland Immunochemicals, Gilbertsville, PA) in the dark for 1 hour at room temperature. The signals were detected using the Odyssey Infrared Imaging System (Li-COR Biosciences, Lincoln, NE) and quantitated with the Image J software program (National Institutes of Health, USA). The ratio for the protein examined was normalized against GAPDH and expressed as mean±SEM.
Cell Culture
Because renal mesangium plays an important role in renal physiology and pathology in response to angiotensin II, 24 ,25 mesangial cells were isolated from both ACE2 WT and knockout mice and cultured in DMEM/F12 supplemented with 10% fetal bovine serum (GIBCO, Carlsbad, CA). Cells at passages 3 to 5 were used for studies. Cells were serum-starved for 16 hours, followed by treatment with angiotensin II (1 μmol/L) for periods of 0 minute, 15 minutes, 30 minutes, 1 hour, 3 hours, and 6 hours for time-dependent mechanistic studies.
Mouse embryonic fibroblasts (MEFs) from Smad3 WT or knockout embryos and Smad2 WT or knockout embryos were obtained as previously described. 23 MEFs were cultured in DMEM/F12 containing 0.5% fetal bovine serum (GIBCO). After starving for 16 hours, MEFs were treated with angiotensin II (1 μmol/L) for periods of 0 minute, 15 minutes, 30 minutes, 1 hour, 3 hours, 6 hours, 9 hours, 12 hours, and 24 hours for miR-21 detection.
Statistical Analysis
Results were expressed as mean±SEM. Statistical analysis including the 1-way ANOVA followed by Newman-Keuls test for multiple comparisons was performed using GraphPad Prism 5.0 (GraphPad Software, San Diego, CA).
Results
ACE2-Deficient Mice Develop Higher Blood Pressure With More Severe Renal Injury Than Wild-Type Mice in Response to Angiotensin II Infusion
After angiotensin II infusion for 28 consecutive days, both ACE2 knockout and WT mice developed hypertension and hypertensive kidney injury (Figure 1 ). However, compared with WT animals, ACE2 knockout mice had higher levels of systolic blood pressure, serum creatinine, and microalbuminuria after Ang II infusion (Figure 1 ).
Angiotensin II-Induced Renal Fibrosis and Inflammation Are Largely Enhanced in ACE2 Knockout Mice
Real-time PCR, immunohistochemistry, and Western blot analysis corroborated that chronic angiotensin II infusion increased the expression and deposition of collagen I and α-SMA in the kidneys of ACE2 WT mice that were further enhanced in ACE2 knockout mice (Figure 2A ; Figure S1 ). Accordingly, angiotensin II-induced renal inflammation, indicated by upregulation of proinflammatory cytokines (IL-1β and tumor necrosis factor α) and chemokine (MCP-1) and by infiltration of CD3 + T cells and F4/80 + macrophages, was also markedly increased in ACE2 knockout mice ( Figure 2B ; Figure S2 ). These results demonstrated that loss of ACE2 promoted progressive renal inflammation and fibrosis in the hypertensive kidney. We next investigated the mechanisms by which ACE2 deficiency enhanced angiotensin II-induced renal fibrosis and inflammation. It is well accepted that Smad7 is able to bind and recruit Smurf2, an E3 ligase, to cause degradation of TGF-β receptor-1 and Smads. 26, 27 In previous studies, we also have found that Smad7 is an integrated protein capable of inactivating NF-κB signaling by increasing IκBα, an inhibitor of NF-κB pathway. 19, 21, [28] [29] [30] We are, thus, prompted to examine whether loss of renal Smad7 is responsible for the worsened hypertensive renal injury in ACE2 knockout mice. Results shown in Figure 3 and Figure S3 clearly demonstrated that chronic angiotensin II infusion induced Smurf2 but reduced renal Smad7 protein, with marked activation of TGF-β/Smad and NF-κB signaling in the kidney of WT mice. All these changes were further enhanced in ACE2 knockout mice. These observations suggest that loss of ACE2 may further promote angiotensin II-induced Smurf2-dependent ubiquitin degradation of Smad7 and that once renal Smad7 is degraded, TGF-β/Smad3-mediated renal fibrosis and NF-κB-driven renal inflammation are enhanced.
Restored Renal Smad7 Rescues Angiotensin II-Induced Renal Injury in ACE2 Knockout Mice by Inactivating TGF-β/Smad3-Mediated Renal Fibrosis and NF-κB-Driven Renal Inflammation
To confirm that loss of renal Smad7 as a mechanism by which ACE2 knockout mice are promoted angiotensin IIinduced progressive renal injury and that overexpression of renal Smad7 has therapeutic potential for accelerated hypertensive nephropathy, Smad7 gene was delivered into the kidneys of angiotensin II-induced hypertensive ACE2 knockout mice on day 3 via the tail vein followed by local ultrasound treatment using the established ultrasound microbubblemediated technique. 18, 19 Results showed that ACE2 knockout mice treated with or without control empty vector developed hypertension with progressive renal damage as evidenced by significantly increased serum creatinine and urinary albumin. On the contrary, renal damage was blunted in the Smad7 treatment group (Figure 4A and 4B) . Interestingly, the presence of enforced Smad7 did not alter angiotensin II-induced increase of systolic blood pressure ( Figure S4 ). Real-time PCR, immunohistochemistry, and Western blot analysis revealed that local renal Smad7 restoration in the kidneys of ACE2 knockout mice abrogated angiotensin II-induced progressive renal fibrosis, evidenced by marked inhibition of collagen I and α-SMA accumulation and TGF-β1 mRNA and protein expression ( Figure 4C ; Figure S5 ). In addition, overexpression of renal Smad7 in ACE2 knockout mice suppressed angiotensin II-induced renal inflammation including upregulation of proinflammatory cytokines (IL-1β, tumor necrosis factor α) and chemokine (MCP-1) and renal infiltration by CD3 + T cells and F4/80 + macrophages ( Figure 4D ; Figure S6 ). We then examined whether Smad7 gene therapy could prevent angiotensin II-induced progressive renal injury in ACE2 knockout mice because Smad7 is an inhibitor of both TGF-β/Smad and NF-κB. Normalization of Smad7 levels in the hypertensive kidney by gene therapy abrogated angiotensin II-induced Smurf2 expression and reduced phosphorylation of Smad2/3, IκBα, and NF-κB/ p65 ( Figure 5 ). Collectively, these findings strongly support a protective role for Smad7 in angiotensin II-mediated progressive kidney injury and its implication for therapeutics development.
Targeting Angiotensin II-Smad3-miR-21 Axis Is Another Mechanism by Which Smad7 Inhibits Renal Fibrosis
Recent studies have shown that miR-21 plays a critical role in TGF-β/Smad3-mediated renal fibrosis in mouse models of unilateral ureteral obstruction and type 2 diabetic nephropathy. 22, 31 To examine whether mice and cells lacking ACE2 promoted angiotensin II-induced renal fibrosis via a Smad3-dependent miR-21 mechanism, we compared ACE2 WT and knockout mice for their miR-21 expression in response to chronic angiotensin II infusion and demonstrated that the exaggerated miR-21 expression in ACE2 knockout mice was completely blocked when renal Smad7 was restored by gene therapy ( Figure 6A and 6B) . We observed also that the deleterious, angiotensin II-induced expression of miR-21 in mesangial cells in vitro was 2-fold higher in ACE2 WT than knockout mice ( Figure 6C ).
We then examined the regulatory mechanism of angiotensin II-induced miR-21 in MEFs obtained from Smad2 or Smad3 knockout mice. Interestingly, addition of angiotensin II was capable of inducing miR-21 expression in MEFs. Surprisingly, angiotensin II-induced miR-21 mRNA expression was abolished in MEFs lacking Smad3; however, deletion of Smad2 produced no inhibitory effect on miR-21 expression in response to angiotensin II ( Figure 6D and 6E).
Discussion
ACE2 is a counter-regulatory enzyme against the ACEangiotensin II-AT1 axis through degradation of angiotensin II. 32 In the present study, we demonstrated that loss of ACE2 promoted angiotensin II-induced renal fibrosis and inflammation by targeting Smad7 for ubiquitin degradation via the Smurf2-dependent mechanism. This was validated by local restoration of Smad7 in the kidneys of ACE2 knockout mice protecting against angiotensin II-induced progressive renal injury. Results from this study suggest that the maladaptive imbalance between angiotensin II and TGF-β/Smad-signaling pathways plays a critical role in the pathogenesis of hypertensive nephropathy.
An interesting observation in this study was that the blood pressure in ACE2 WT and knockout mice were similar at baseline, but when challenged with chronic angiotensin II infusion, the blood pressure was significantly increased in mice lacking ACE2. This indicates that the protective functions of ACE2 may not be essential under physiological resting conditions because other enzymes with convergent functionalities, including neprilysin, prolyl-endopeptidase, and thimet oligopeptidase, may compensate for the loss of ACE2 function to degrade angiotensin I and angiotensin II to angiotensin 1-7. 33, 34 However, under stress and chronic disease conditions emulated by chronic angiotensin II infusion, these compensatory pathways are functionally insufficient, and, thus, mice lacking ACE2 develop more severe hypertension and hypertensive kidney damage. In addition, because vascular inflammation can augment hypertension (or vice versa) caused by angiotensin II, 35 it may be postulated that elevated blood pressure in ACE2 knockout mice is secondary to increased vascular inflammation. However, treatment with Smad7 did improve angiotensin II-induced progressive renal injury without altering the systemic blood pressure. These findings, therefore, suggest that the increased blood pressure in the ACE2 knockout animal is primarily because of a loss of local renal ACE2 rather than heightened systemic vascular inflammation. Furthermore, inhibition of TGF-β/Smad3-mediated renal fibrosis and NF-κB-driven renal inflammation may be mechanisms by which restoration of renal Smad7 ameliorated kidney damage (as indicated by levels of serum creatinine and urinary albumin) in ACE2 knockout mice.
A significant finding from the present study is that Smurf2-dependent ubiquitin degradation of Smad7 may be essential for triggering angiotensin II-induced renal fibrosis and inflammation in ACE2 knockout mice via the TGF-β/ Smad3-dependent and NF-κB-dependent mechanisms. We have previously shown that angiotensin II can activate Smad2/3 directly via the AT1-MAKP (mitogen-activated protein kinase)-Smad crosstalk pathway. 36 Activation of Smad3 can then transcriptionally induce Smurf2, an E3 ligase, which binds and causes degradation of Smad7 protein. 26, 27 It is also reported that Smurf2-mediated degradation of renal Smad7 protein plays a pathogenic role in the progression of tubulointerstitial fibrosis, and this degradation pathway is negatively regulated by AIMP1/p43, which works as an inhibitor of TGF-β signaling by binding Smurf2 and inhibit Smurf2-dependent degradation of Smad7. 37, 38 Because Smad7 functions as an integrated inhibitor for both TGF-β/Smad-signaling and NF-κB-signaling pathways, 18, 19, 21, [28] [29] [30] once renal Smad7 is degraded, TGF-β/Smad and NF-κB signaling becomes activated, resulting in the development of renal fibrosis and inflammation. We have previously shown that Smad7 is renoprotective in hypertension, as deletion of Smad7 enhances whereas overexpression of renal Smad7 inhibits angiotensin II-induced hypertensive heart and kidney injury. [39] [40] [41] [42] In this study, we provided further evidence for an essential role of Smad7 in protection against angiotensin II-induced kidney injury under accelerated hypertensive conditions in ACE2 knockout mice. Mice lacking ACE2 developed more severe hypertension and hypertensive nephropathy, which was associated with a marked activation of the Smurf2-dependent Smad7 ubiquitin degradation pathway. This may well explain that TGF-β/Smad3-mediated renal fibrosis and NF-κB-driven renal inflammation were largely enhanced in ACE2 knockout mice in response to chronic angiotensin II infusion. Direct evidence for the protective role of renal Smad7 in hypertensive nephropathy has come from our finding that locally restored Smad7 in the kidneys of ACE2 knockout mice can protect the hypertensive kidney from angiotensin II-induced, TGF-β/Smad3-mediated renal fibrosis and NF-κB-driven renal inflammation. Thus, results from this study are meaningful because these imply that Smad7 may be a novel therapeutic agent for hypertensive nephropathy even under progressive disease conditions.
Increasing evidence shows that TGF-β1 regulates renal fibrosis in kidney diseases through many Smad3-dependent microRNAs. 43 We have previously reported that deletion of Smad7 enhances angiotensin II-induced loss of miR-29b and promoted renal injury via a Smad3-dependent mechanism, 40 which is reversed by the overexpression of Smad7. 44 In the present study, we added new evidence for angiotensin II-induced miR-21 expression via a Smad3-dependent mechanism through which ACE2 knockout mice developed progressive renal fibrosis. In contrast, restoring renal Smad7 in ACE2 knockout mice led to inhibited renal fibrosis by inactivating Smad3 and suppressing miR-21 expression. This is consistent with the previous observation that miR-21 binds 3′ untranslated region of Smad7 gene sequence and inhibits Smad7 transcription to promote renal fibrosis in obstructive and diabetic kidney diseases, 22, 29, 45, 46 whereas overexpression of renal Smad7 protects against renal fibrosis by suppressing renal miR-21. 44 Taken together, loss of ACE2 may enhance angiotensin II-induced renal fibrosis via the Smad3-miR-21-Smad7 pathway and that Smad7 protects against angiotensin II-induced progressive renal injury by targeting the Smad3-miR-21 axis.
Perspectives
Disrupted ACE2 largely enhances angiotensin II-induced Smurf2-dependent Smad7 ubiquitin degradation, thereby promoting TGF-β/Smad3-miR-21-mediated renal fibrosis and NF-κB-driven renal inflammation. In contrast, restored renal Smad7 in ACE2 knockout mice protects against progressive renal injury by blocking TGF-β/Smad3-miR-21-mediated renal fibrosis and NF-κB-driven renal inflammation. Findings from this study demonstrate that balancing angiotensin II-TGF-β/Smad-NF-κB signaling pathways by overexpressing Smad7 may be a novel therapeutic strategy for hypertensive nephropathy. 
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